Form 4: Instil Bio Director Receives Stock Option Grant

Director R. Kent McGaughy Jr. was granted 6,500 stock options in Instil Bio, Inc. as part of the company's equity incentive plan.

Summary

• Director R. Kent McGaughy Jr. acquired 6,500 stock options in Instil Bio, Inc. (TIL).
• The options have an exercise price of $7.93 per share.
• The grant date for the transaction was June 11, 2026.
• The options are set to expire on June 10, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Vesting is contingent upon the director's continuous service to the company.
• Market price volatility may impact the future value of the granted options.

Future Outlook

The options vest in 12 substantially equal monthly installments starting July 11, 2026, with full acceleration upon death, disability, or a change in control.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to ensure board retention and alignment with corporate performance milestones.

Comparison to Industry Standards

• The use of a 12-month vesting schedule for director options is consistent with standard corporate governance practices for small-cap biotech firms.
• The grant size is relatively modest, reflecting standard annual director compensation packages.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution if options are exercised.

Next Steps

• Vesting of options to commence on July 11, 2026.

Key Dates

Keywords

Instil Bio, TIL, Form 4, Insider Trading, Stock Options, Director Compensation